Wednesday, May 23, 2012
Celtic Pharmaceutical Holdings LP, of New York, said it completed a Phase I/II study of Xerecept (corticorelin acetate) in pediatric patients who are dependent on the steroid Decadron (dexamethasone) to treat peritumoral brain edema associated with cerebral tumors. Initial indications from the 15-patient study indicated that Xerecept can reduce or eliminate the need for Decadron use and provide significant quality of life improvements.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.